Drug Profile
DX 0332
Alternative Names: DX-0332Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator DermaXon
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Neuropathic-pain(Chemotherapy-induced) in USA
- 06 Jul 2018 DermaXon recieves Phase I STTR grant from the National Institute of Neurological Disorders and Stroke for preclinical efficacy studies for the treatment of Peripheral neuropathy
- 19 Jul 2016 Early research in Peripheral nervous system diseases (Chemotherapy-induced) in USA (unspecified route)